Test Code TBGI Thyroxine-Binding Globulin (TBG), Serum
Reporting Name
Thyroxine Binding Globulin, SUseful For
Cases in which total thyroid hormone levels do not correlate with thyrometabolic status, most commonly with pregnancy or the use of contraceptive steroids
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumSpecimen Required
Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).
Supplies: Sarstedt Aliquot Tube 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL serum
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
Serum: 0.35 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 7 days |
| Frozen | 30 days |
Day(s) Performed
Monday, Wednesday, Friday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
84442
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| TBGI | Thyroxine Binding Globulin, S | 3021-3 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| TBGI | Thyroxine Binding Globulin, S | 3021-3 |
Clinical Information
Thyroxine binding globulin (TBG) is the high-affinity serum binding protein for thyroxine and triiodothyronine. Normally, the thyroid adjusts to changing concentrations of TBG by producing more, or less, thyroid hormone to maintain a constant level of metabolically important free hormone.
Elevated TBG levels are associated with influences such as pregnancy, genetic predisposition, oral contraceptives, and estrogen therapy. TBG levels can decrease with androgenic or anabolic steroids, large doses of glucocorticoids, hypoproteinemic states, liver disease, nephrotic syndrome, and congenital TBG variants.
Cautions
Female individuals using estrogen-based contraception may exceed the reference range.
The drug asfotase alfa (STRENSIQ), a recombinant form of alkaline phosphatase, is expected to interfere with in vitro diagnostic assays with alkaline phosphatase detection systems, such as this assay. Patients taking asfotase alfa should utilize testing with a non-alkaline phosphatase methodology.
Report Available
1 to 3 daysSpecimen Retention Time
2 weeksReject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
Method Name
Solid-Phase Chemiluminescent Assay